Synflorix regulatory update

GlaxoSmithKline disclosed in its 1Q14 earnings that Japan Vaccine Co. Ltd. (Tokyo, Japan) submitted an application to Japan's Ministry of Health, Labor and Welfare (MHLW) for Synflorix to prevent invasive disease, acute otitis media and pneumonia due to Streptococcus pneumoniae in infants. The company declined to comment on when it expects a decision in Japan. Japan Vaccine is a 50/50 JV between GSK and Daiichi Sankyo Co. Ltd. (Tokyo:4568, Tokyo, Japan). ...